Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces they are supporting an educational satellite symposium on: “Expanding the options in MF-CTCL: changing the present, shaping the future”. The symposium will be heldat the EORTC CLTF 2018 Annual Meeting in St. Gallen, Switzerland, taking place 27-29 September 2018.

The symposium will take place on Thursday 27 September, 12:45 – 13:45, Hall 9.2, Olma Messen, St Gallen, Switzerland.

This educational symposium will bring together a panel of leading experts in the treatment of Cutaneous Lymphoma, to compare and provide an update on the current treatment options of Mycosis Fungoides Cutaneous T-cell lymphoma (MF-CTCL).

The event will outline the current landscape of MF-CTCL treatment and will provide a better understanding of the planned and ongoing research in this specific area. Moreover, the future of MF-CTCL treatment options will be deeply discussed. This session will also highlight new potential treatment options, as well as research on the mechanism of action of chlormethine.

The full program is available at the following link.

Silvia Sebastiani, Head of Medical Affairs at the Helsinn Group, commented: “Helsinn remains committed to improve the life and well-being of cancer patients. We are delighted to support and bring together this educational symposium to make an overview on the latest research on MF-CTCL, with the final aim of expanding and improving treatments options for patients living with this type of cancer.”

Julia J. Scarisbrick, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, said: “We are very pleased to have the support of the Helsinn Group in bringing together this expert panel at the EORTC annual meeting, and to have put together a stimulating and educational symposium. Over half of CTCL patients are diagnosed with MF-CTCL, and there is no cure for this rare skin cancer. This symposium will be important for the future exploration of treatment options for these patients.”